Skip to Content
Authors Lucey MR
Author Profile(s)
Journal Clin Liver Dis Volume: 13 Issue: 2 Pages: 267-75
Publish Date 2009 May
PubMed ID 19442918
Abstract

Understanding alcohol addiction and abstinence is key to treating alcoholic liver disease, since abstinence leads to improvement in all forms of alcoholic liver damage. Although pharmacotherapy for alcoholism, using agents such as naltrexone, acamprosate, topiramate, and baclofen, is an exciting field, few studies have included patients with liver disease or cirrhosis. To treat alcoholic liver injury, corticosteroids have become the standard of care in patients with severe alcoholic hepatitis. In contrast, the role of pharmacotherapy to treat alcoholic fibrosis is unclear, with failure to observe a benefit in randomized, placebo-controlled clinical trials of colchicine, S-adenosylmethionine (SAMe), or phosphatidylcholine. Liver transplantation remains an option in selected patients with life-threatening alcoholic liver disease.

webmaster@surgery.wisc.edu Copyright © 2016 The Board of Regents of the University of Wisconsin System